Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Chevron
CVX
|
+$331M |
| 2 |
Walmart
WMT
|
+$229M |
| 3 |
Linde
LIN
|
+$187M |
| 4 |
PayPal
PYPL
|
+$145M |
| 5 |
Union Pacific
UNP
|
+$126M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$903M |
| 2 |
Uber
UBER
|
+$565M |
| 3 |
Exxon Mobil
XOM
|
+$450M |
| 4 |
Novo Nordisk
NVO
|
+$393M |
| 5 |
Apple
AAPL
|
+$317M |
Sector Composition
| 1 | Technology | 18.82% |
| 2 | Healthcare | 17.05% |
| 3 | Consumer Discretionary | 13.22% |
| 4 | Financials | 8.79% |
| 5 | Consumer Staples | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2651
PIMCO Investment Grade Corporate Bond Index Exchange-Traded Fund
CORP
$1.34B
| $768K | ﹤0.01% |
+8,000
| New | +$768K |
|
2652
Nine Energy Service
NINE
$30.5M
| $768K | ﹤0.01% |
342,836
-135,100
| -28% | -$303K |
|
2653
MSC Industrial Direct
MSM
$5.09B
| $767K | ﹤0.01% |
7,900
-95,100
| -92% | -$9.23M |
|
2654
Vanguard Consumer Discretionary ETF
VCR
$6.58B
| $763K | ﹤0.01% |
+2,400
| New | +$763K |
|
2655
Vanguard Global ex-US Real Estate ETF
VNQI
$3.62B
| $763K | ﹤0.01% |
+18,100
| New | +$763K |
|
2656
SPDR S&P 400 Mid Cap Value ETF
MDYV
$2.47B
| $762K | ﹤0.01% |
10,025
-275
| -3% | -$20.9K |
|
|
PMD
2657
DELISTED
Psychemedics Corporation
PMD
| $761K | ﹤0.01% |
259,863
-5,700
| -2% | -$16.7K |
|
|
GHG
2658
GreenTree Hospitality
GHG
$227M
| $760K | ﹤0.01% |
244,281
-19,808
| -8% | -$61.6K |
|
2659
Enterprise Financial Services Corp
EFSC
$2.24B
| $759K | ﹤0.01% |
18,704
+11,904
| +175% | +$483K |
|
2660
eHealth
EHTH
$122M
| $759K | ﹤0.01% |
125,828
+8,600
| +7% | +$51.9K |
|
2661
iShares MSCI Italy ETF
EWI
$729M
| $758K | ﹤0.01% |
20,100
-23,400
| -54% | -$882K |
|
|
FGNX
2662
FG Nexus Inc. Common Stock
FGNX
$9.69M
| $756K | ﹤0.01% |
21,908
+20,173
| +1,163% | +$696K |
|
2663
Village Farms International
VFF
$297M
| $755K | ﹤0.01% |
608,566
+155,300
| +34% | +$193K |
|
|
SII
2664
Sprott
SII
$1.8B
| $750K | ﹤0.01% |
20,300
-28,100
| -58% | -$1.04M |
|
2665
Greenwich LifeSciences
GLSI
$153M
| $748K | ﹤0.01% |
37,500
+900
| +2% | +$18K |
|
2666
Ponce Financial Group
PDLB
$336M
| $747K | ﹤0.01% |
83,894
+1,000
| +1% | +$8.9K |
|
2667
Granite Ridge Resources
GRNT
$705M
| $742K | ﹤0.01% |
114,100
-133,000
| -54% | -$865K |
|
|
ILPT
2668
Industrial Logistics Properties Trust
ILPT
$424M
| $741K | ﹤0.01% |
172,800
-196,500
| -53% | -$843K |
|
2669
Schwab International Equity ETF
SCHF
$51.3B
| $741K | ﹤0.01% |
38,000
-85,200
| -69% | -$1.66M |
|
2670
Absci
ABSI
$381M
| $740K | ﹤0.01% |
130,300
-300
| -0.2% | -$1.7K |
|
2671
Hydrofarm Holdings
HYFM
$15.3M
| $740K | ﹤0.01% |
68,480
+3,630
| +6% | +$39.2K |
|
2672
United Security Bancshares
UBFO
$165M
| $740K | ﹤0.01% |
96,044
-804
| -0.8% | -$6.2K |
|
2673
Praxis Precision Medicines
PRAX
$794M
| $739K | ﹤0.01% |
12,104
-68,700
| -85% | -$4.19M |
|
2674
Invesco China Technology ETF
CQQQ
$1.5B
| $737K | ﹤0.01% |
23,010
-15,090
| -40% | -$483K |
|
2675
Acrivon Therapeutics
ACRV
$47.8M
| $734K | ﹤0.01% |
+102,600
| New | +$734K |
|